PCSK9 acts as a negative regulator of the low‐density lipoprotein (LDL) receptor and is primarily expressed in the liver.[35] Inhibiting PCSK9 has proven effective in reducing serum cholesterol levels and holds promise for reducing the risk of coronary heart disease.[2] We designed four sgRNAs targeting Pcsk9 exon 1 and tested their activity in murine hepatoma cells (Hepa1‐6, Figure 4a). This evidence concerns the gene PCSK9 and hepatocellular carcinoma.